Document is current
Any future updates will be listed below
-
Authors
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Abouqateb, Mouad
Peczynski, Christophe
Boreland, William
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Stelljes, Matthias
Gedde-Dahl, Tobias
Blau, Igor Wolfgang
Schroeder, Thomas
Salmenniemi, Urpu
Kulagin, Alexander https://orcid.org/0000-0002-9589-4136
Peffault de Latour, Régis
Mielke, Stephan https://orcid.org/0000-0003-0167-6021
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Moiseev, Ivan
Schoemans, Hélène https://orcid.org/0000-0002-7568-8239
Koenecke, Christian https://orcid.org/0000-0001-7025-1735
Peric, Zinaida
- License Information
-
More Information
Article History
Received: 19 January 2024
Revised: 6 March 2024
Accepted: 8 March 2024
First Online: 27 March 2024
Competing interests
: OP has received honoraria or travel support from Gilead, Jazz, MSD, Novartis, Pfizer and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution. She has also received non-financial support from Gilead, Pfizer, the EBMT (European Society for Blood and Marrow transplantation) and the CIBMTR (Center for International Bone Marrow Transplantation Research). IM received honoraria or travel support from Novartis, Sanofi, SOBI, Takeda. CCL received honoraria or travel support from Gilead/Kite and Therakos. Consulting fees for advisory board from Gilead/Kite, Nektar Therapeutics. FB participated to AB and received speaker fees from NEOVII and SANOFI. PD reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi, Novartis, Riemser; speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Novartis, Riemser, Roche; research support from Riemser (all to institution). RZ received speaker fees from Novartis, Incytem Neovii, MNK and Sanofi.
: The study was approved by the EBMT review board. Patients had to sign an informed consent document that permitted sharing of clinical data according to national rules.
